CD8A and neoplasm: All of the Dexo vaccine formulations tested were able to increase the frequency of TRP2-specific CD8+ T cells as compared to saline treatment, but only vaccination with Dexo(B16 + pIC) resulted in significantly increased TRP2-specific CD8+ T lymphocytes as compared to saline and to the other Dexo formulations, not only in the tdLNs (1.32%) and spleens (0.94%) but also in the tumor masses of treated mice (9.7%) (Fig. 5c).